Article info
PDFClinical and epidemiological research
Concise report
Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
- Correspondence to Professor Jacques-Eric Gottenberg, ImmunoRhumatologie Moléculaire, Service de Rhumatologie, INSERM UMR_S 1109, Université de Strasbourg, Centre National de Référence des Maladies Auto-Immunes, Hôpital Hautepierre, 1 Avenue Molière, 67000 Strasbourg 67098, France; jacques-eric.gottenberg@chru-strasbourg.fr
Citation
Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Publication history
- Received July 2, 2012
- Revised October 12, 2012
- Accepted November 18, 2012
- First published December 21, 2012.
Online issue publication
May 26, 2023
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions